The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).
Males and females ages 18 years and older with a pre- existing kidney transplant from an HLA-matched living donor.
Pre-existing living kidney transplant must be within 3 months to 5 years from date of scheduled HPSC infusion.
No history of rejection with current HLA matched kidney transplant.
Recipient is without post-transplant major complications, including de novo malignancy, active infection or rejection.
Donor is identical twin.
Major ABO incompatibility with donor
Positive HLA Donor-Specific Antibody (DSA)
History of multi-organ transplantation